Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Radiopharmaceutical

Radiopharmaceutical Comprehensive Study by Type (Diagnostic Radioisotopes, Therapeutic Radioisotopes), Application (Oncology, Cardiology, Neurology, Thyroid), Procedures (Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-Urinary, Pulmonary), Radioisotope (Technetium-99, Gallium-67, Iodine-123, 18F, Rubidium-82, Yttrium-90, Lutetium-177), Modality (SPECT, PET, Alpha-Emitters, Beta-Emitters, Brachytherapy), Source (Nuclear Reactors, Cyclotrons), End User (Hospitals and Diagnostic Centers, Research Institutes) Players and Region - Global Market Outlook to 2028

Radiopharmaceutical Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 8.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Growth stage driven by rising number of cancer cases and increasing awareness about nuclear medicine will help to boost global radio-pharmaceutical market in the foretasted period. Unique medicinal formulations containing radioisotopes are called to as radio-pharmaceuticals. It is pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis as well as therapeutics. Radio-pharmaceuticals are divided into four major categories namely radio-pharmaceutical preparation (medicinal ready to use suitable for human product containing a radionuclide), radio-pharmaceutical precursor (a radionuclide produced for radio-labeling), radionuclide generator (a system which generates a daughter radionuclide), and radio-pharmaceutical preparation kit (vial containing non-radionuclide components of a radio-pharmaceutical preparation).

AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledCardinal Health (United States), GE Healthcare (United States), Curium (France), Bayer (Germany), Lantheus Medical Imaging (United States), Advanced Accelerator Applications (France), Jubilant Life Sciences (India), Mallinckrodt plc. (United Kingdom), Medtronic, Inc. (Ireland) and Cardinal Health, Inc. (United States)


According to AMA, the market for Radiopharmaceutical is expected to register a CAGR of 8.4% during the forecast period to 2028. This growth is primarily driven by Initiatives to Lessen the Demand-Supply Gap of Mo-99 and Growing Patient Awareness Levels Demanding Accurate Diagnosis.

Globally, a noticeable market trend is evident Growing Demand for Alpha Radioimmunotherapy-Based Targeted Cancer Treatment The Pharmaceuticals sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Cardinal Health (United States), GE Healthcare (United States), Curium (France), Bayer (Germany), Lantheus Medical Imaging (United States), Advanced Accelerator Applications (France), Jubilant Life Sciences (India), Mallinckrodt plc. (United Kingdom), Medtronic, Inc. (Ireland) and Cardinal Health, Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 2nd May 2018, Curium signed an agreement to acquire Cyclopharma’s manufacturing and commercial operations in France.
On 26th January 2018, AAA received US FDA Approval for LUTATHERA used in the treatment of gastroenteropancreatic neuroendocrine tumors.

Influencing Trend:
Growing Demand for Alpha Radioimmunotherapy-Based Targeted Cancer Treatment and Increasing Incidence of Cardiac Patients and Adoption Of Clear Imaging Technique

Market Growth Drivers:
Initiatives to Lessen the Demand-Supply Gap of Mo-99 and Growing Patient Awareness Levels Demanding Accurate Diagnosis

Challenges:
High Capital Investment Required

Restraints:
Rising Concern Regarding Short Half-Life of Radio-pharmaceuticals and Supply Shortages and Limited Number of Trained Medical Personnel.

Opportunities:
Huge Demand Due To Use of Radio-pharmaceuticals in Neurological Applications and Technological Advancement in Applications of Molecular Imaging

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Radiopharmaceutical Market
- Analysis about New Entrants in Radiopharmaceutical Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Radiopharmaceutical Study Sheds Light on
— The Radiopharmaceutical Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Radiopharmaceutical industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Radiopharmaceutical industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Diagnostic Radioisotopes
  • Therapeutic Radioisotopes
By Application
  • Oncology
  • Cardiology
  • Neurology
  • Thyroid
By Procedures
  • Central Nervous System
  • Endocrine
  • Skeletal
  • Gastrointestinal
  • Genito-Urinary
  • Pulmonary

By Radioisotope
  • Technetium-99
  • Gallium-67
  • Iodine-123
  • 18F
  • Rubidium-82
  • Yttrium-90
  • Lutetium-177

By Modality
  • SPECT
  • PET
  • Alpha-Emitters
  • Beta-Emitters
  • Brachytherapy

By Source
  • Nuclear Reactors
  • Cyclotrons

By End User
  • Hospitals and Diagnostic Centers
  • Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Initiatives to Lessen the Demand-Supply Gap of Mo-99
      • 3.2.2. Growing Patient Awareness Levels Demanding Accurate Diagnosis
    • 3.3. Market Challenges
      • 3.3.1. High Capital Investment Required
    • 3.4. Market Trends
      • 3.4.1. Growing Demand for Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
      • 3.4.2. Increasing Incidence of Cardiac Patients and Adoption Of Clear Imaging Technique
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radiopharmaceutical, by Type, Application, Procedures, Radioisotope, Modality, Source, End User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Radiopharmaceutical (Value)
      • 5.2.1. Global Radiopharmaceutical by: Type (Value)
        • 5.2.1.1. Diagnostic Radioisotopes
        • 5.2.1.2. Therapeutic Radioisotopes
      • 5.2.2. Global Radiopharmaceutical by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Cardiology
        • 5.2.2.3. Neurology
        • 5.2.2.4. Thyroid
      • 5.2.3. Global Radiopharmaceutical by: Procedures (Value)
        • 5.2.3.1. Central Nervous System
        • 5.2.3.2. Endocrine
        • 5.2.3.3. Skeletal
        • 5.2.3.4. Gastrointestinal
        • 5.2.3.5. Genito-Urinary
        • 5.2.3.6. Pulmonary
      • 5.2.4. Global Radiopharmaceutical by: Radioisotope (Value)
        • 5.2.4.1. Technetium-99
        • 5.2.4.2. Gallium-67
        • 5.2.4.3. Iodine-123
        • 5.2.4.4. 18F
        • 5.2.4.5. Rubidium-82
        • 5.2.4.6. Yttrium-90
        • 5.2.4.7. Lutetium-177
      • 5.2.5. Global Radiopharmaceutical by: Modality (Value)
        • 5.2.5.1. SPECT
        • 5.2.5.2. PET
        • 5.2.5.3. Alpha-Emitters
        • 5.2.5.4. Beta-Emitters
        • 5.2.5.5. Brachytherapy
      • 5.2.6. Global Radiopharmaceutical by: Source (Value)
        • 5.2.6.1. Nuclear Reactors
        • 5.2.6.2. Cyclotrons
      • 5.2.7. Global Radiopharmaceutical by: End User (Value)
        • 5.2.7.1. Hospitals and Diagnostic Centers
        • 5.2.7.2. Research Institutes
      • 5.2.8. Global Radiopharmaceutical Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global Radiopharmaceutical (Price)
      • 5.3.1. Global Radiopharmaceutical by: Type (Price)
  • 6. Radiopharmaceutical: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cardinal Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GE Healthcare (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Curium (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lantheus Medical Imaging (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Advanced Accelerator Applications (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Jubilant Life Sciences (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mallinckrodt plc. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Medtronic, Inc. (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cardinal Health, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Radiopharmaceutical Sale, by Type, Application, Procedures, Radioisotope, Modality, Source, End User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Radiopharmaceutical (Value)
      • 7.2.1. Global Radiopharmaceutical by: Type (Value)
        • 7.2.1.1. Diagnostic Radioisotopes
        • 7.2.1.2. Therapeutic Radioisotopes
      • 7.2.2. Global Radiopharmaceutical by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Cardiology
        • 7.2.2.3. Neurology
        • 7.2.2.4. Thyroid
      • 7.2.3. Global Radiopharmaceutical by: Procedures (Value)
        • 7.2.3.1. Central Nervous System
        • 7.2.3.2. Endocrine
        • 7.2.3.3. Skeletal
        • 7.2.3.4. Gastrointestinal
        • 7.2.3.5. Genito-Urinary
        • 7.2.3.6. Pulmonary
      • 7.2.4. Global Radiopharmaceutical by: Radioisotope (Value)
        • 7.2.4.1. Technetium-99
        • 7.2.4.2. Gallium-67
        • 7.2.4.3. Iodine-123
        • 7.2.4.4. 18F
        • 7.2.4.5. Rubidium-82
        • 7.2.4.6. Yttrium-90
        • 7.2.4.7. Lutetium-177
      • 7.2.5. Global Radiopharmaceutical by: Modality (Value)
        • 7.2.5.1. SPECT
        • 7.2.5.2. PET
        • 7.2.5.3. Alpha-Emitters
        • 7.2.5.4. Beta-Emitters
        • 7.2.5.5. Brachytherapy
      • 7.2.6. Global Radiopharmaceutical by: Source (Value)
        • 7.2.6.1. Nuclear Reactors
        • 7.2.6.2. Cyclotrons
      • 7.2.7. Global Radiopharmaceutical by: End User (Value)
        • 7.2.7.1. Hospitals and Diagnostic Centers
        • 7.2.7.2. Research Institutes
      • 7.2.8. Global Radiopharmaceutical Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global Radiopharmaceutical (Price)
      • 7.3.1. Global Radiopharmaceutical by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radiopharmaceutical: by Type(USD Million)
  • Table 2. Radiopharmaceutical Diagnostic Radioisotopes , by Region USD Million (2017-2022)
  • Table 3. Radiopharmaceutical Therapeutic Radioisotopes , by Region USD Million (2017-2022)
  • Table 4. Radiopharmaceutical: by Application(USD Million)
  • Table 5. Radiopharmaceutical Oncology , by Region USD Million (2017-2022)
  • Table 6. Radiopharmaceutical Cardiology , by Region USD Million (2017-2022)
  • Table 7. Radiopharmaceutical Neurology , by Region USD Million (2017-2022)
  • Table 8. Radiopharmaceutical Thyroid , by Region USD Million (2017-2022)
  • Table 9. Radiopharmaceutical: by Procedures(USD Million)
  • Table 10. Radiopharmaceutical Central Nervous System , by Region USD Million (2017-2022)
  • Table 11. Radiopharmaceutical Endocrine , by Region USD Million (2017-2022)
  • Table 12. Radiopharmaceutical Skeletal , by Region USD Million (2017-2022)
  • Table 13. Radiopharmaceutical Gastrointestinal , by Region USD Million (2017-2022)
  • Table 14. Radiopharmaceutical Genito-Urinary , by Region USD Million (2017-2022)
  • Table 15. Radiopharmaceutical Pulmonary , by Region USD Million (2017-2022)
  • Table 16. Radiopharmaceutical: by Radioisotope(USD Million)
  • Table 17. Radiopharmaceutical Technetium-99 , by Region USD Million (2017-2022)
  • Table 18. Radiopharmaceutical Gallium-67 , by Region USD Million (2017-2022)
  • Table 19. Radiopharmaceutical Iodine-123 , by Region USD Million (2017-2022)
  • Table 20. Radiopharmaceutical 18F , by Region USD Million (2017-2022)
  • Table 21. Radiopharmaceutical Rubidium-82 , by Region USD Million (2017-2022)
  • Table 22. Radiopharmaceutical Yttrium-90 , by Region USD Million (2017-2022)
  • Table 23. Radiopharmaceutical Lutetium-177 , by Region USD Million (2017-2022)
  • Table 24. Radiopharmaceutical: by Modality(USD Million)
  • Table 25. Radiopharmaceutical SPECT , by Region USD Million (2017-2022)
  • Table 26. Radiopharmaceutical PET , by Region USD Million (2017-2022)
  • Table 27. Radiopharmaceutical Alpha-Emitters , by Region USD Million (2017-2022)
  • Table 28. Radiopharmaceutical Beta-Emitters , by Region USD Million (2017-2022)
  • Table 29. Radiopharmaceutical Brachytherapy , by Region USD Million (2017-2022)
  • Table 30. Radiopharmaceutical: by Source(USD Million)
  • Table 31. Radiopharmaceutical Nuclear Reactors , by Region USD Million (2017-2022)
  • Table 32. Radiopharmaceutical Cyclotrons , by Region USD Million (2017-2022)
  • Table 33. Radiopharmaceutical: by End User(USD Million)
  • Table 34. Radiopharmaceutical Hospitals and Diagnostic Centers , by Region USD Million (2017-2022)
  • Table 35. Radiopharmaceutical Research Institutes , by Region USD Million (2017-2022)
  • Table 36. South America Radiopharmaceutical, by Country USD Million (2017-2022)
  • Table 37. South America Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 38. South America Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 39. South America Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 40. South America Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 41. South America Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 42. South America Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 43. South America Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 44. Brazil Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 45. Brazil Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 46. Brazil Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 47. Brazil Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 48. Brazil Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 49. Brazil Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 50. Brazil Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 51. Argentina Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 52. Argentina Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 53. Argentina Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 54. Argentina Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 55. Argentina Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 56. Argentina Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 57. Argentina Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 58. Rest of South America Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 59. Rest of South America Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 60. Rest of South America Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 61. Rest of South America Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 62. Rest of South America Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 63. Rest of South America Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 64. Rest of South America Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 65. Asia Pacific Radiopharmaceutical, by Country USD Million (2017-2022)
  • Table 66. Asia Pacific Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 67. Asia Pacific Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 68. Asia Pacific Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 69. Asia Pacific Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 70. Asia Pacific Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 71. Asia Pacific Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 72. Asia Pacific Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 73. China Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 74. China Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 75. China Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 76. China Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 77. China Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 78. China Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 79. China Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 80. Japan Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 81. Japan Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 82. Japan Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 83. Japan Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 84. Japan Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 85. Japan Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 86. Japan Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 87. India Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 88. India Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 89. India Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 90. India Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 91. India Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 92. India Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 93. India Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 94. South Korea Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 95. South Korea Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 96. South Korea Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 97. South Korea Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 98. South Korea Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 99. South Korea Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 100. South Korea Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 101. Taiwan Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 102. Taiwan Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 103. Taiwan Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 104. Taiwan Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 105. Taiwan Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 106. Taiwan Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 107. Taiwan Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 108. Australia Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 109. Australia Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 110. Australia Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 111. Australia Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 112. Australia Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 113. Australia Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 114. Australia Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 115. Rest of Asia-Pacific Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 116. Rest of Asia-Pacific Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 117. Rest of Asia-Pacific Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 118. Rest of Asia-Pacific Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 119. Rest of Asia-Pacific Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 120. Rest of Asia-Pacific Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 121. Rest of Asia-Pacific Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 122. Europe Radiopharmaceutical, by Country USD Million (2017-2022)
  • Table 123. Europe Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 124. Europe Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 125. Europe Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 126. Europe Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 127. Europe Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 128. Europe Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 129. Europe Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 130. Germany Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 131. Germany Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 132. Germany Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 133. Germany Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 134. Germany Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 135. Germany Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 136. Germany Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 137. France Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 138. France Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 139. France Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 140. France Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 141. France Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 142. France Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 143. France Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 144. Italy Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 145. Italy Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 146. Italy Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 147. Italy Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 148. Italy Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 149. Italy Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 150. Italy Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 151. United Kingdom Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 152. United Kingdom Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 153. United Kingdom Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 154. United Kingdom Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 155. United Kingdom Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 156. United Kingdom Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 157. United Kingdom Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 158. Netherlands Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 159. Netherlands Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 160. Netherlands Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 161. Netherlands Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 162. Netherlands Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 163. Netherlands Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 164. Netherlands Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 165. Rest of Europe Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 166. Rest of Europe Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 167. Rest of Europe Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 168. Rest of Europe Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 169. Rest of Europe Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 170. Rest of Europe Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 171. Rest of Europe Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 172. MEA Radiopharmaceutical, by Country USD Million (2017-2022)
  • Table 173. MEA Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 174. MEA Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 175. MEA Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 176. MEA Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 177. MEA Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 178. MEA Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 179. MEA Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 180. Middle East Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 181. Middle East Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 182. Middle East Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 183. Middle East Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 184. Middle East Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 185. Middle East Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 186. Middle East Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 187. Africa Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 188. Africa Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 189. Africa Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 190. Africa Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 191. Africa Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 192. Africa Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 193. Africa Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 194. North America Radiopharmaceutical, by Country USD Million (2017-2022)
  • Table 195. North America Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 196. North America Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 197. North America Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 198. North America Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 199. North America Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 200. North America Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 201. North America Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 202. United States Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 203. United States Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 204. United States Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 205. United States Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 206. United States Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 207. United States Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 208. United States Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 209. Canada Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 210. Canada Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 211. Canada Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 212. Canada Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 213. Canada Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 214. Canada Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 215. Canada Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 216. Mexico Radiopharmaceutical, by Type USD Million (2017-2022)
  • Table 217. Mexico Radiopharmaceutical, by Application USD Million (2017-2022)
  • Table 218. Mexico Radiopharmaceutical, by Procedures USD Million (2017-2022)
  • Table 219. Mexico Radiopharmaceutical, by Radioisotope USD Million (2017-2022)
  • Table 220. Mexico Radiopharmaceutical, by Modality USD Million (2017-2022)
  • Table 221. Mexico Radiopharmaceutical, by Source USD Million (2017-2022)
  • Table 222. Mexico Radiopharmaceutical, by End User USD Million (2017-2022)
  • Table 223. Radiopharmaceutical: by Type(USD/Units)
  • Table 224. Company Basic Information, Sales Area and Its Competitors
  • Table 225. Company Basic Information, Sales Area and Its Competitors
  • Table 226. Company Basic Information, Sales Area and Its Competitors
  • Table 227. Company Basic Information, Sales Area and Its Competitors
  • Table 228. Company Basic Information, Sales Area and Its Competitors
  • Table 229. Company Basic Information, Sales Area and Its Competitors
  • Table 230. Company Basic Information, Sales Area and Its Competitors
  • Table 231. Company Basic Information, Sales Area and Its Competitors
  • Table 232. Company Basic Information, Sales Area and Its Competitors
  • Table 233. Company Basic Information, Sales Area and Its Competitors
  • Table 234. Radiopharmaceutical: by Type(USD Million)
  • Table 235. Radiopharmaceutical Diagnostic Radioisotopes , by Region USD Million (2023-2028)
  • Table 236. Radiopharmaceutical Therapeutic Radioisotopes , by Region USD Million (2023-2028)
  • Table 237. Radiopharmaceutical: by Application(USD Million)
  • Table 238. Radiopharmaceutical Oncology , by Region USD Million (2023-2028)
  • Table 239. Radiopharmaceutical Cardiology , by Region USD Million (2023-2028)
  • Table 240. Radiopharmaceutical Neurology , by Region USD Million (2023-2028)
  • Table 241. Radiopharmaceutical Thyroid , by Region USD Million (2023-2028)
  • Table 242. Radiopharmaceutical: by Procedures(USD Million)
  • Table 243. Radiopharmaceutical Central Nervous System , by Region USD Million (2023-2028)
  • Table 244. Radiopharmaceutical Endocrine , by Region USD Million (2023-2028)
  • Table 245. Radiopharmaceutical Skeletal , by Region USD Million (2023-2028)
  • Table 246. Radiopharmaceutical Gastrointestinal , by Region USD Million (2023-2028)
  • Table 247. Radiopharmaceutical Genito-Urinary , by Region USD Million (2023-2028)
  • Table 248. Radiopharmaceutical Pulmonary , by Region USD Million (2023-2028)
  • Table 249. Radiopharmaceutical: by Radioisotope(USD Million)
  • Table 250. Radiopharmaceutical Technetium-99 , by Region USD Million (2023-2028)
  • Table 251. Radiopharmaceutical Gallium-67 , by Region USD Million (2023-2028)
  • Table 252. Radiopharmaceutical Iodine-123 , by Region USD Million (2023-2028)
  • Table 253. Radiopharmaceutical 18F , by Region USD Million (2023-2028)
  • Table 254. Radiopharmaceutical Rubidium-82 , by Region USD Million (2023-2028)
  • Table 255. Radiopharmaceutical Yttrium-90 , by Region USD Million (2023-2028)
  • Table 256. Radiopharmaceutical Lutetium-177 , by Region USD Million (2023-2028)
  • Table 257. Radiopharmaceutical: by Modality(USD Million)
  • Table 258. Radiopharmaceutical SPECT , by Region USD Million (2023-2028)
  • Table 259. Radiopharmaceutical PET , by Region USD Million (2023-2028)
  • Table 260. Radiopharmaceutical Alpha-Emitters , by Region USD Million (2023-2028)
  • Table 261. Radiopharmaceutical Beta-Emitters , by Region USD Million (2023-2028)
  • Table 262. Radiopharmaceutical Brachytherapy , by Region USD Million (2023-2028)
  • Table 263. Radiopharmaceutical: by Source(USD Million)
  • Table 264. Radiopharmaceutical Nuclear Reactors , by Region USD Million (2023-2028)
  • Table 265. Radiopharmaceutical Cyclotrons , by Region USD Million (2023-2028)
  • Table 266. Radiopharmaceutical: by End User(USD Million)
  • Table 267. Radiopharmaceutical Hospitals and Diagnostic Centers , by Region USD Million (2023-2028)
  • Table 268. Radiopharmaceutical Research Institutes , by Region USD Million (2023-2028)
  • Table 269. South America Radiopharmaceutical, by Country USD Million (2023-2028)
  • Table 270. South America Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 271. South America Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 272. South America Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 273. South America Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 274. South America Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 275. South America Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 276. South America Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 277. Brazil Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 278. Brazil Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 279. Brazil Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 280. Brazil Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 281. Brazil Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 282. Brazil Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 283. Brazil Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 284. Argentina Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 285. Argentina Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 286. Argentina Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 287. Argentina Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 288. Argentina Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 289. Argentina Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 290. Argentina Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 291. Rest of South America Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 292. Rest of South America Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 293. Rest of South America Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 294. Rest of South America Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 295. Rest of South America Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 296. Rest of South America Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 297. Rest of South America Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 298. Asia Pacific Radiopharmaceutical, by Country USD Million (2023-2028)
  • Table 299. Asia Pacific Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 300. Asia Pacific Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 301. Asia Pacific Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 302. Asia Pacific Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 303. Asia Pacific Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 304. Asia Pacific Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 305. Asia Pacific Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 306. China Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 307. China Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 308. China Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 309. China Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 310. China Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 311. China Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 312. China Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 313. Japan Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 314. Japan Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 315. Japan Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 316. Japan Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 317. Japan Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 318. Japan Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 319. Japan Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 320. India Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 321. India Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 322. India Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 323. India Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 324. India Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 325. India Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 326. India Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 327. South Korea Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 328. South Korea Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 329. South Korea Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 330. South Korea Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 331. South Korea Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 332. South Korea Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 333. South Korea Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 334. Taiwan Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 335. Taiwan Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 336. Taiwan Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 337. Taiwan Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 338. Taiwan Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 339. Taiwan Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 340. Taiwan Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 341. Australia Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 342. Australia Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 343. Australia Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 344. Australia Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 345. Australia Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 346. Australia Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 347. Australia Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 348. Rest of Asia-Pacific Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 349. Rest of Asia-Pacific Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 350. Rest of Asia-Pacific Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 351. Rest of Asia-Pacific Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 352. Rest of Asia-Pacific Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 353. Rest of Asia-Pacific Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 354. Rest of Asia-Pacific Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 355. Europe Radiopharmaceutical, by Country USD Million (2023-2028)
  • Table 356. Europe Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 357. Europe Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 358. Europe Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 359. Europe Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 360. Europe Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 361. Europe Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 362. Europe Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 363. Germany Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 364. Germany Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 365. Germany Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 366. Germany Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 367. Germany Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 368. Germany Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 369. Germany Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 370. France Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 371. France Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 372. France Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 373. France Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 374. France Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 375. France Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 376. France Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 377. Italy Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 378. Italy Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 379. Italy Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 380. Italy Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 381. Italy Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 382. Italy Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 383. Italy Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 384. United Kingdom Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 385. United Kingdom Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 386. United Kingdom Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 387. United Kingdom Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 388. United Kingdom Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 389. United Kingdom Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 390. United Kingdom Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 391. Netherlands Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 392. Netherlands Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 393. Netherlands Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 394. Netherlands Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 395. Netherlands Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 396. Netherlands Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 397. Netherlands Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 398. Rest of Europe Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 399. Rest of Europe Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 400. Rest of Europe Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 401. Rest of Europe Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 402. Rest of Europe Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 403. Rest of Europe Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 404. Rest of Europe Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 405. MEA Radiopharmaceutical, by Country USD Million (2023-2028)
  • Table 406. MEA Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 407. MEA Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 408. MEA Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 409. MEA Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 410. MEA Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 411. MEA Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 412. MEA Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 413. Middle East Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 414. Middle East Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 415. Middle East Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 416. Middle East Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 417. Middle East Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 418. Middle East Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 419. Middle East Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 420. Africa Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 421. Africa Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 422. Africa Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 423. Africa Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 424. Africa Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 425. Africa Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 426. Africa Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 427. North America Radiopharmaceutical, by Country USD Million (2023-2028)
  • Table 428. North America Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 429. North America Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 430. North America Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 431. North America Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 432. North America Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 433. North America Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 434. North America Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 435. United States Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 436. United States Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 437. United States Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 438. United States Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 439. United States Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 440. United States Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 441. United States Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 442. Canada Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 443. Canada Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 444. Canada Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 445. Canada Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 446. Canada Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 447. Canada Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 448. Canada Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 449. Mexico Radiopharmaceutical, by Type USD Million (2023-2028)
  • Table 450. Mexico Radiopharmaceutical, by Application USD Million (2023-2028)
  • Table 451. Mexico Radiopharmaceutical, by Procedures USD Million (2023-2028)
  • Table 452. Mexico Radiopharmaceutical, by Radioisotope USD Million (2023-2028)
  • Table 453. Mexico Radiopharmaceutical, by Modality USD Million (2023-2028)
  • Table 454. Mexico Radiopharmaceutical, by Source USD Million (2023-2028)
  • Table 455. Mexico Radiopharmaceutical, by End User USD Million (2023-2028)
  • Table 456. Radiopharmaceutical: by Type(USD/Units)
  • Table 457. Research Programs/Design for This Report
  • Table 458. Key Data Information from Secondary Sources
  • Table 459. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radiopharmaceutical: by Type USD Million (2017-2022)
  • Figure 5. Global Radiopharmaceutical: by Application USD Million (2017-2022)
  • Figure 6. Global Radiopharmaceutical: by Procedures USD Million (2017-2022)
  • Figure 7. Global Radiopharmaceutical: by Radioisotope USD Million (2017-2022)
  • Figure 8. Global Radiopharmaceutical: by Modality USD Million (2017-2022)
  • Figure 9. Global Radiopharmaceutical: by Source USD Million (2017-2022)
  • Figure 10. Global Radiopharmaceutical: by End User USD Million (2017-2022)
  • Figure 11. South America Radiopharmaceutical Share (%), by Country
  • Figure 12. Asia Pacific Radiopharmaceutical Share (%), by Country
  • Figure 13. Europe Radiopharmaceutical Share (%), by Country
  • Figure 14. MEA Radiopharmaceutical Share (%), by Country
  • Figure 15. North America Radiopharmaceutical Share (%), by Country
  • Figure 16. Global Radiopharmaceutical: by Type USD/Units (2017-2022)
  • Figure 17. Global Radiopharmaceutical share by Players 2022 (%)
  • Figure 18. Global Radiopharmaceutical share by Players (Top 3) 2022(%)
  • Figure 19. Global Radiopharmaceutical share by Players (Top 5) 2022(%)
  • Figure 20. BCG Matrix for key Companies
  • Figure 21. Cardinal Health (United States) Revenue, Net Income and Gross profit
  • Figure 22. Cardinal Health (United States) Revenue: by Geography 2022
  • Figure 23. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 24. GE Healthcare (United States) Revenue: by Geography 2022
  • Figure 25. Curium (France) Revenue, Net Income and Gross profit
  • Figure 26. Curium (France) Revenue: by Geography 2022
  • Figure 27. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer (Germany) Revenue: by Geography 2022
  • Figure 29. Lantheus Medical Imaging (United States) Revenue, Net Income and Gross profit
  • Figure 30. Lantheus Medical Imaging (United States) Revenue: by Geography 2022
  • Figure 31. Advanced Accelerator Applications (France) Revenue, Net Income and Gross profit
  • Figure 32. Advanced Accelerator Applications (France) Revenue: by Geography 2022
  • Figure 33. Jubilant Life Sciences (India) Revenue, Net Income and Gross profit
  • Figure 34. Jubilant Life Sciences (India) Revenue: by Geography 2022
  • Figure 35. Mallinckrodt plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Mallinckrodt plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 37. Medtronic, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 38. Medtronic, Inc. (Ireland) Revenue: by Geography 2022
  • Figure 39. Cardinal Health, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Cardinal Health, Inc. (United States) Revenue: by Geography 2022
  • Figure 41. Global Radiopharmaceutical: by Type USD Million (2023-2028)
  • Figure 42. Global Radiopharmaceutical: by Application USD Million (2023-2028)
  • Figure 43. Global Radiopharmaceutical: by Procedures USD Million (2023-2028)
  • Figure 44. Global Radiopharmaceutical: by Radioisotope USD Million (2023-2028)
  • Figure 45. Global Radiopharmaceutical: by Modality USD Million (2023-2028)
  • Figure 46. Global Radiopharmaceutical: by Source USD Million (2023-2028)
  • Figure 47. Global Radiopharmaceutical: by End User USD Million (2023-2028)
  • Figure 48. South America Radiopharmaceutical Share (%), by Country
  • Figure 49. Asia Pacific Radiopharmaceutical Share (%), by Country
  • Figure 50. Europe Radiopharmaceutical Share (%), by Country
  • Figure 51. MEA Radiopharmaceutical Share (%), by Country
  • Figure 52. North America Radiopharmaceutical Share (%), by Country
  • Figure 53. Global Radiopharmaceutical: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Cardinal Health (United States)
  • GE Healthcare (United States)
  • Curium (France)
  • Bayer (Germany)
  • Lantheus Medical Imaging (United States)
  • Advanced Accelerator Applications (France)
  • Jubilant Life Sciences (India)
  • Mallinckrodt plc. (United Kingdom)
  • Medtronic, Inc. (Ireland)
  • Cardinal Health, Inc. (United States)
Additional players considered in the study are as follows:
IBA Group (Czech Republic) , Covidien Plc (Ireland) , Positron Corporation (United States) , NTP Radioisotopes Pty Ltd. (South Africa)
Select User Access Type

Key Highlights of Report


Apr 2023 222 Pages 82 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Radiopharmaceutical Quantitative research analysis
Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Radiopharmaceutical Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Radiopharmaceutical market are Cardinal Health (United States), GE Healthcare (United States), Curium (France), Bayer (Germany), Lantheus Medical Imaging (United States), Advanced Accelerator Applications (France), Jubilant Life Sciences (India), Mallinckrodt plc. (United Kingdom), Medtronic, Inc. (Ireland) and Cardinal Health, Inc. (United States), to name a few.
North America is dominating the Radiopharmaceutical Market.
"High Capital Investment Required" is seen as one of the major challenges by many Industry Players of Radiopharmaceutical Market
The Radiopharmaceutical market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Radiopharmaceutical market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Radiopharmaceutical Report?

Have a Query? Click Here

Other Related Reports

Pet Medication Comprehensive Study by Type (Antibiotics, Antimicrobials, Antiparasitics, Chemotherapeutics), Application (Cat, Dog, Horse, Fish, Other), Distribution Channel (Online Channel, Offline ...
$ 3500
Anti-Infective Drugs Comprehensive Study by Type (Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs), Indication (Candidiasis, Aspergillosis, HIV Infection, Sepsis, Hepatitis Virus Infection,...
$ 3750
Doctor Bags Comprehensive Study by Type (Leather Bags, Cotton Bags, Canvas Bags, Nylon Bags, Other), Application (Women, Men), Distribution Chanel (Online, Offline) Players and Region - Global Market...
$ 3500
Phenylketonuria Drug Comprehensive Study by Type (Medications, Supplements , Others), Application (Household, Hospital, Others), Symtomps (Classic, Mild, Benign), Test (Diagnostic Test, Screening Tes...
$ 3500
Pneumonia Vaccine Comprehensive Study by Type (Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23)), Patient Type (Pediatric Patients, Adult Patients), Distribution C...
$ 3350
Scopolamine Comprehensive Study by Type (Scopolamine Butylbromide, Scopolamine Hydrobromide, Scopolamine Base), Application (Oral, Injection, Patches), Form (Tablet, Syrup), Distribution Channel (Hos...
$ 3650